Suppr超能文献

特发性腹膜后纤维化的类固醇治疗:剂量与疗程

Steroid therapy for idiopathic retroperitoneal fibrosis: dose and duration.

作者信息

Kardar A H, Kattan S, Lindstedt E, Hanash K

机构信息

Department of Urology, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia.

出版信息

J Urol. 2002 Aug;168(2):550-5.

Abstract

PURPOSE

Idiopathic retroperitoneal fibrosis is an uncommon disease of unknown etiology that may involve the ureters and other retroperitoneal structures. Surgical ureterolysis as well as medical treatment with steroids have been used to treat these patients. However, there is no agreement as to the dose and duration of steroid. We adopted a regimen of long-term steroid use in this prospective study.

MATERIALS AND METHODS

We treated 12 patients with idiopathic retroperitoneal fibrosis with a regimen of steroids during a 10-year period. Tissue diagnosis was established by biopsy of all lesions and ureteral obstruction was managed with insertion of a nephrostomy tube or a ureteral stent. The initial dose of prednisolone was 60 mg. on alternate days for 2 months and was tapered during the following 2 months to a daily dose of 5 mg. The total duration of prednisolone use was 2 years.

RESULTS

Of the 12 patients 11 who completed this treatment regimen have been followed for a duration of 26 to 132 months (median 63.1) after discontinuation of treatment. Good response in the form of relief of symptoms and regression of the mass occurred in 9 cases and there were 2 failures. In 1 case the retroperitoneal mass did not regress and surgical ureterolysis was required. In the 2nd case symptoms recurred after discontinuation of steroid and a further small dose of steroids was required. Function deteriorated in 1 of 19 functioning renal units. No steroid related serious side effects developed.

CONCLUSIONS

This regimen of steroid may be used as the primary mode of treatment for the majority of patients with idiopathic retroperitoneal fibrosis with minimal complications. Patients with idiopathic retroperitoneal fibrosis should be followed periodically for the rest of their lives.

摘要

目的

特发性腹膜后纤维化是一种病因不明的罕见疾病,可累及输尿管及其他腹膜后结构。手术输尿管松解术以及使用类固醇进行药物治疗均已用于治疗这些患者。然而,对于类固醇的剂量和疗程尚无共识。在这项前瞻性研究中,我们采用了长期使用类固醇的方案。

材料与方法

我们在10年期间用类固醇方案治疗了12例特发性腹膜后纤维化患者。通过对所有病变进行活检确立组织诊断,并通过插入肾造瘘管或输尿管支架来处理输尿管梗阻。泼尼松龙的初始剂量为隔日60毫克,持续2个月,并在接下来的2个月内逐渐减量至每日5毫克。泼尼松龙的总使用时间为2年。

结果

12例患者中,11例完成该治疗方案的患者在停药后随访了26至132个月(中位时间63.1个月)。9例患者症状缓解且肿块消退,治疗效果良好,2例治疗失败。1例患者腹膜后肿块未消退,需要进行手术输尿管松解术。第2例患者在停用类固醇后症状复发,需要再次使用小剂量类固醇。19个有功能的肾单位中有1个功能恶化。未出现与类固醇相关的严重副作用。

结论

这种类固醇方案可作为大多数特发性腹膜后纤维化患者的主要治疗方式,并发症最少。特发性腹膜后纤维化患者应在余生中定期随访。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验